Edoxaban and the issue of drug-drug interactions: from pharmacology to clinical practice
A Corsini, N Ferri, M Proietti, G Boriani - Drugs, 2020 - Springer
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
A Corsini, N Ferri, M Proietti, G Boriani - DRUGS, 2020 - air.unimi.it
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
A Corsini, N Ferri, M Proietti, G Boriani - Drugs, 2020 - pubmed.ncbi.nlm.nih.gov
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug‑Drug Interactions: From Pharmacology to Clinical Practice
A Corsini, N Ferri, M Proietti, G Boriani - Drugs, 2020 - search.proquest.com
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.
A Corsini, N Ferri, M Proietti, G Boriani - Drugs, 2020 - search.ebscohost.com
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
A Corsini, N Ferri, M Proietti, G Boriani - DRUGS, 2020 - iris.unimore.it
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice.
A Corsini, N Ferri, M Proietti, G Boriani - Drugs, 2020 - europepmc.org
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
Edoxaban and the Issue of Drug-Drug Interactions: From Pharmacology to Clinical Practice
A Corsini, N Ferri, M Proietti, G Boriani - DRUGS, 2020 - research.unipd.it
Edoxaban, a direct factor Xa inhibitor, is the latest of the non-vitamin K antagonist oral
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …
anticoagulants (NOACs). Despite being marketed later than other NOACs, its use is now …